Perampanel — Membership Pricing

Other medications in Neurological

• Phenobarbital
• Ponesimod
• Pramipexole
• Promethazine
• Propranolol
• Rasagiline
• Riluzole
• Rimegepant

About Perampanel

Perampanel is a medication prescribed to help manage certain types of seizures in individuals with epilepsy. As a member of TheDrugClub, you can gain access to significant savings on your prescription medications, including perampanel. We're dedicated to making essential treatments more affordable, ensuring you can focus on your health without the added financial strain.

Perampanel: Targeting Seizures with a Unique Mechanism

Perampanel, often known by its brand name Fycompa, is an anti-epileptic drug (AED) that plays a crucial role in managing specific forms of epilepsy. It is primarily used to treat partial-onset seizures, with or without secondary generalization, in patients aged 4 years and older. Additionally, it is approved as an adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures in individuals 12 years and older. For many living with epilepsy, finding an effective treatment that minimizes side effects is a continuous journey, and perampanel offers a distinct option.

How Perampanel Works in the Brain

Unlike many traditional AEDs, perampanel operates through a unique mechanism of action. It is a selective, non-competitive antagonist of the AMPA receptor, a type of glutamate receptor found in the brain. Glutamate is the primary excitatory neurotransmitter in the central nervous system, and excessive activation of AMPA receptors can lead to neuronal overactivity, which is a hallmark of seizures. By blocking these receptors, perampanel reduces the excessive electrical activity in the brain, helping to stabilize neuronal function and prevent seizures. This novel approach makes it a valuable option, particularly for patients who may not have responded well to other anti-epileptic medications.

Navigating the Cost of Perampanel

As a brand-name medication, perampanel can be quite expensive without insurance or a robust savings program. The typical cost can vary significantly based on the dosage, quantity prescribed, and the pharmacy you choose. Without any discounts, a month's supply could potentially run into hundreds of dollars. These costs can be a significant barrier for many patients needing consistent access to their medication.

Save on Perampanel with TheDrugClub

At TheDrugClub, we understand the importance of affordable medication. As a member, you gain access to a network of pharmacies offering competitive pricing on prescriptions like perampanel. While we never

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Perampanel is approved for (FDA label)

Perampanel, a non-competitive AMPA glutamate receptor antagonist, is indicated for: Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older ( 1.2 ) 1.1 Partial-Onset Seizures Perampanel oral suspension is indicated for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older. 1.2 Primary Generalized Tonic-Clonic Seizures Perampanel oral suspension is indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.

Source: Read the full FDA label on DailyMed. Label effective date: June 2, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Perampanel (FDA label)

WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and threats have been reported in patients taking perampanel ( 5.1 ). These reactions occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated with hostility and aggression ( 5.1 ). Advise patients and caregivers to contact a healthcare provider immediately if any of these reactions or changes in mood, behavior, or personality that are not typical for the patient are observed while taking perampanel or after discontinuing perampanel ( 5.1 ). Closely monitor patients particularly during the titration period and at higher doses ( 5.1 ). Perampanel should be reduced if these symptoms occur and should be discontinued immediately if symptoms are severe or are worsening ( 5.1 ). WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS See full prescribing information for complete boxed warning. Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and threats have been reported in patients taking perampanel ( 5.1 ) Monitor patients for these reactions as well as for changes in mood, behavior, or personality that are not typical for the patient, particularly during the titration period and at higher doses ( 5.1 ) Perampanel should be reduced if these symptoms occur and should be discontinued immediately if symptoms are severe or are worsening ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: 3c72a5f7-bb22-4c48-942a-543ca84ed5a9. SPL document ID: 5348f497-343a-0a74-e063-6394a90ab38b. Label effective date: June 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Perampanel (FDA label)

Oral Suspension: 0.5 mg/mL ( 3 ) Oral Suspension 0.5 mg/mL white to off-white, homogenous suspension for oral administration.

Source: FDA prescribing information (DailyMed). Set ID: 3c72a5f7-bb22-4c48-942a-543ca84ed5a9. SPL document ID: 5348f497-343a-0a74-e063-6394a90ab38b. Label effective date: June 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Perampanel (FDA label)

The following serious adverse reactions are described below and elsewhere in the labeling: Serious Psychiatric and Behavioral Reactions [see Warnings and Precautions (5.1) ] Suicidal Behavior and Ideation [see Warnings and Precautions (5.2) ] Neurologic Effects [see Warnings and Precautions (5.3) ] Falls [see Warnings and Precautions (5.4) ] Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity [see Warnings and Precautions (5.5) ] Most common adverse reactions (≥5% and ≥1% higher than placebo) include dizziness, somnolence, fatigue, irritability, falls, nausea, weight gain, vertigo, ataxia, headache, vomiting, contusion, abdominal pain, and anxiety ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc., at 1-866-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: 3c72a5f7-bb22-4c48-942a-543ca84ed5a9. SPL document ID: 5348f497-343a-0a74-e063-6394a90ab38b. Label effective date: June 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Perampanel (FDA label)

None. None ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 3c72a5f7-bb22-4c48-942a-543ca84ed5a9. SPL document ID: 5348f497-343a-0a74-e063-6394a90ab38b. Label effective date: June 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Perampanel (FDA label)

Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behavior ( 5.2 ) Neurologic Effects: Monitor for dizziness, gait disturbance, somnolence, and fatigue ( 5.3 ) Patients should use caution when driving or operating machinery ( 5.3 ) Falls: Monitor for falls and injuries ( 5.4 ) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/ Multi-Organ Hypersensitivity: Discontinue if no alternate etiology ( 5.5 ) Withdrawal of Antiepileptic Drugs: In patients with epilepsy, there may be an increase in seizure frequency ( 5.6 ) 5.1 Serious Psychiatric and Behavioral Reactions In the controlled partial-onset seizure clinical trials, hostility- and aggression-related adverse reactions occurred in 12% and 20% of patients randomized to receive perampanel at doses of 8 mg and 12 mg per day, respectively, compared to 6% of patients in the placebo group.

Source: FDA prescribing information (DailyMed). Set ID: 3c72a5f7-bb22-4c48-942a-543ca84ed5a9. SPL document ID: 5348f497-343a-0a74-e063-6394a90ab38b. Label effective date: June 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Perampanel (FDA label)

Contraceptives: 12 mg once daily may decrease the effectiveness of hormonal contraceptives containing levonorgestrel ( 7.1 ) Moderate and Strong CYP3A4 Inducers (including carbamazepine, oxcarbazepine, and phenytoin): increase clearance of perampanel and decrease perampanel plasma concentrations. When moderate or strong CYP3A4 inducers are introduced or withdrawn, monitor patients closely. Dose adjustment of perampanel may be necessary ( 2.3 , 7.2 ) 7.1 Contraceptives With concomitant use, perampanel at a dose of 12 mg per day reduced levonorgestrel exposure by approximately 40% [see Clinical Pharmacology (12.3) ] . Use of perampanel with contraceptives containing levonorgestrel may render them less effective.

Source: FDA prescribing information (DailyMed). Set ID: 3c72a5f7-bb22-4c48-942a-543ca84ed5a9. SPL document ID: 5348f497-343a-0a74-e063-6394a90ab38b. Label effective date: June 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.